ArticleScientific reports2021
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Colorimetric Ready-to-Use Microfluidic Chips for Rapid Antibiotic Susceptibility Testing of Methicillin-ResistantACS omega · 2026Article
- Article
- Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma.Scientific reports · 2025Article
- Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA.Journal of racial and ethnic health disparities · 2024Article
- ANCA: artificial nucleic acid circuit with argonaute protein for one-step isothermal detection of antibiotic-resistant bacteria.Nature communications · 2023Article
- Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects.The Journal of infectious diseases · 2023Article
- MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection.Pathogens (Basel, Switzerland) · 2023Article
- High SARS-CoV-2 seroprevalence among street adolescents in Lomé, Togo, 2021.BMC infectious diseases · 2023Article
- Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria.Journal of clinical virology plus · 2023Article
- Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population.PLOS global public health · 2023Article
- Directly immersible silicon photonic probes: Application to rapid SARS-CoV-2 serological testing.Biosensors & bioelectronics · 2022Article
- Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens.Heliyon · 2022Article
- Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants.Microbiology spectrum · 2022Article
- Performance of SARS-CoV-2 Antigens in a Multiplex Bead Assay for Integrated Serological Surveillance of Neglected Tropical and Other Diseases.The American journal of tropical medicine and hygiene · 2022Article
- Evaluation of a Multiplex Bead Assay against Single-Target Assays for Detection of IgG Antibodies to SARS-CoV-2.Microbiology spectrum · 2022Article
- Multiplexed flow cytometric approach for detection of anti-SARS-CoV-2 IgG, IgM and IgA using beads covalently coupled to the nucleocapsid protein.Letters in applied microbiology · 2022Article
- Article
- SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era.Diagnostics (Basel, Switzerland) · 2022Article
- Rapid and accurate clinical testing for COVID-19 by nicking and extension chain reaction system-based amplification (NESBA).Biosensors & bioelectronics · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical performance, there is growing evidence regarding their limitations in epidemiological serosurveys. To address this, we developed a Luminex-based multiplex immunoassay that detects total antibodies (IgG/IgM/IgA) against the N, S1 and RBD antigens and used it to compare antibody responses in 1225 blood donors across Greece. Seroprevalence based on single-antigen readouts was strongly influenced by both the antigen type and cut-off value and ranged widely [0.8% (95% CI 0.4-1.5%)-7.5% (95% CI 6.0-8.9%)]. A multi-antigen approach requiring partial agreement between RBD and N or S1 readouts (RBD&N|S1 rule) was less affected by cut-off selection, resulting in robust seroprevalence estimation [0.6% (95% CI 0.3-1.1%)-1.2% (95% CI 0.7-2.0%)] and accurate identification of seroconverted individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.